Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy.

ABSTRACT:

Introduction

The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported when it is used as a component of antiretroviral therapy regimens in treatment-experienced patients unless there was prior use of a first-generation integrase inhibitor.

Patient presentation

A 38-year-old woman diagnosed with tuberculosis was switched to a second-line antiretroviral regimen of zidovudine, lamivudine and dolutegravir 50 mg 12-hourly together with rifampicin-based TB treatment. Based on treatment history and a previous resistance test there was resistance to lamivudine but full susceptibility to zidovudine. The patient did not suppress her viral load on this regimen and later admitted to only

SUBMITTER: Mahomed K 

PROVIDER: S-EPMC7433307 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature